论文部分内容阅读
目的:探究在介入治疗原发肝癌的临床治疗中,奥沙利铂联合表柔比星的治疗效果和不良反应。方法:采用介入治疗原发肝癌的方法对我院收治的112例患者进行治疗,按照用药方案的不同将其分为对照组(56例)与研究组(56例),分别给予奥沙利铂灌注并碘化油栓塞、奥沙利铂灌注并碘化油混合表柔比星栓塞治疗,并对两组的治疗效果和不良反应发生情况方面进行研究比较。结果:在治疗效果方面,对照组与研究组的总有效率分别为68.56%、91.62%,P<0.05,差异具有统计学意义;在不良反应情况方面,对照组有15例(32.25%),研究组有13例(28.92%),差异无统计学意义(P>0.05)。结论:在介入治疗原发肝癌的临床治疗中,相对于采用单一的奥沙利铂化疗栓塞,奥沙利铂联合表柔比星栓塞的效果更好,不良反应较少,具有较高的安全性,应该大力推广。
Objective: To explore the therapeutic effect and adverse reactions of oxaliplatin combined with epirubicin in the interventional treatment of primary liver cancer. Methods: One hundred and twelve patients admitted to our hospital were treated by interventional treatment of primary hepatocellular carcinoma (HCC). The patients were divided into control group (56 cases) and study group (56 cases) according to different dosage regimen. Patients were given oxaliplatin Perfusion and iodized oil embolism, oxaliplatin perfusion and iodized oil mixed epirubicin embolization, and the two groups of treatment and adverse reactions were compared. Results: The total effective rates of the control group and the study group were 68.56% and 91.62%, respectively, with significant difference between the two groups (P <0.05). There were 15 cases (32.25%) of the adverse reactions in the control group, The study group had 13 cases (28.92%), the difference was not statistically significant (P> 0.05). Conclusion: In the interventional treatment of primary hepatocellular carcinoma, oxaliplatin combined with epirubicin is better than oxaliplatin in the treatment of primary liver cancer with fewer side effects and higher safety Sex, should be vigorously promoted.